June 22, 2022

Pfizer To Invest $95 Mln In Valneva; Updates Deal Terms For Lyme Disease Vaccine Candidate VLA15

(RTTNews) – Pfizer Inc. (PFE) and Valneva SE (VALN), a French specialty vaccine company, announced Monday that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15.

This post was originally published on this site

Sign Up To Get FREE News, Tips and Offers!

X